Lexicon Genetics tests LX6171 in cognitive disorders trial

By Elaine Rigoli

Tampa, Fla., Sept. 6 - Lexicon Genetics, Inc. has started a phase 1 clinical trial for LX6171, a novel, orally administered small-molecule compound for cognitive disorders.

The trial initiation follows the clearance in July of The Woodlands, Texas-based company's Clinical Trial Authorization filing for LX6171 by the United Kingdom Medicines and Healthcare Products Regulatory Agency.

The biopharmaceutical company said the trial is being conducted in normal healthy volunteers and is designed as a randomized, double-blind, ascending single-dose study with about 40 subjects.

The company said LX6171 is a selective and potent inhibitor of a novel membrane protein that is expressed exclusively in the central nervous system and is associated with synaptic vesicles and presynaptic membranes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.